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1. Introduction 
While the first uses of skin transplantation may be found in anecdotal images  involving the 
use of foreign tissue to cover burns and damaged skin, the modern era of skin grafting 
attempts to understand the phenomenon scientifically. One well documented case describes 
Joseph E. Murray’s surgical procedure to use skin from a recently deceased person to cover 
the skin of a pilot who suffered disfiguring burns in 1944 (Murray, 1992)  The transplanted 
skin survived for more than thirty days, despite any predictions of rejection that might have 
destroyed the tissue in two weeks or less. Murray hypothesized that the procedure was 
successful because of the weakened state of the recipient’s immune system. Murray 
continued his interest in transplantation immunology, and ten years later his team was the 
first to engraft an organ from a living donor, (Murray, 1992).  
In 1944 Medawar described rejection of allografts, that is, organs or tissues exchanged 
between individuals of the same species (Medawar, 1944). His pioneering work described 
the consequences of allograft and autograft transplantation in exquisite detail. He used the 
rabbit skin model to show differences in acceptance of autografts, using the same individual 
or same strain as the tissue source, vs. allografts that exchanged skin between different 
animals of the same species. He further used meticulously measured tissue size as a 
surrogate marker for skin antigen dose and documented the process of healing for 
autographs opposed to the “actively acquired immune reactions” that resulted in the 
necrosis of allografts. R. E. Billingham (1959) reviewed the fate of engrafted tissue that is 
rejected by the host in light of the then recently discovered major histocompatibility 
complex in the mouse (MHC). The MHC genes encode cell surface proteins that allow the 
immune system to discriminate between its own cells and foreign cells. Billingham 
referenced the use of isogenic mouse strains wherein each animal of the strain has identical 
MHC genes, and these animal models facilitated the understanding of graft versus host 
disease, rejection mediated by immunocompetent cells within a graft (Billingham, 1959).  
Billingham, Brent, and Medawar (1953) described immunological tolerance that is actively 
acquired following prenatal exposure to foreign tissue in a mouse model. This phenomenon 
described the survival of engrafted tissue, whereas the same tissue generated immunity 
resulting in graft destruction when transplanted in the adult. After eight weeks, the tolerant 
mice were challenged with adult skin of the same donor origin as the primary transplant, in 
order to evaluate the persistence of tolerance. These experiments documented the utility of 
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mouse models as a practical means to help us understand immunological processes. Five 
years later, Billingham and Silvers (1958) induced specific tolerance to the male chromosome 
associated Y antigen in neonatal female mice, again using the skin graft model. Researchers 
continue to use these basic methods to uncover the underlying mechanism of tolerance and 
immunity.  
Skin grafts, with their enhanced antigenicity and abundant supplies of antigen presenting 
cells,   remain a vigorous test of any tolerance induction system (Murray, 1971, Nasir et al., 
2009, Tobin et al., 2009, Akdis, 2010, van den Berg et al., 2011, Kaplan, 2010, del Rio et al., 
2010). Some of the skin associated antigens include autoantigens found on keratinocytes and 
appear to induce T lymphocyte reactivity that results in skin eruptions (Jackman et al., 
2002). Antigenicity of skin has remained a concern for those promoting translational 
medicine, including those who promote the use of composite tissue allografts (Swearingen 
et al., 2008). The grafting of composite tissue is often used in limb replacement surgery. 
These grafts consist of  complex combinations of multiple tissue types, including skin, 
adipose tissue, bone and others (Siemionow et al., 2009). The complexity of these composite 
tissue allografts is such that a new classification system was devised in order to accurately 
describe their attributes. Tissue antigenicity is one of the criteria on which the classification 
system is based (Gordon et al., 2009). These historical experiments helped to usher in the era 
of modern skin transplantation. 
2. Generalized Immunosuppression to facilitate skin graft acceptance 
Medical science has pursued a multiplicity of scientific directions in order to utilize   solid 
organ transplantation as a potential cure for life-threatening diseases and as a treatment for 
sever disfigurement. Organ transplantation has been referred to as “One of the most 
remarkable achievements of medicine during the 20th century” (Goldstein, 2011). Scientific 
advances gleaned from the use of skin grafts and other tissue and organ grafts have restored 
tissue function, extended the life, and promoted the general well-being of the graft host. The 
spoken or unspoken hypothesis behind the use of generalized immunosuppression may be 
stated as follows: If the immune system in an otherwise healthy individual is capable of 
recognizing foreign tissue and mounting an attack against it, then significantly reducing all 
such recognition may allow for engrafted tissue to remain intact and functional. Many of 
these procedures required protracted or life-long treatments with unanticipated or negative 
sequelae (Ingvar et al., 2010, Berardinelli et al., 2009). The goal of these broad-based 
protocols was to protect the viability of the graft in order to protect the life of the host. Some 
notable examples of the use of generalized immunosuppressive agents are described below. 
2.1 Three categories of drugs targeting lymphocytes have been described 
Information gleaned from reviews in major journals describes three general categories of 
immunosuppressive agents (Halloran, 2004, Lindenfeld et al., 2004, Gonzalez Posada, 2006, 
1970). These include antibodies directed against lymphocytes, steroids, and agents that 
interfere with metabolism or that have toxic effects on cells. The first category is often 
referred to as antilymphocyte or antithymocyte globulin (ALG or ATG). ALG in 
combination with an intrathymic dose of donor spleen cells was shown to induce graft 
survival in a rat model (Shen et al., 1996). Lewis-Brown Norway cardiac allografts showed 
extensive survival in Lewis rats; whereas skin grafts from the same donor strain were 
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rejected at a similar rate as third party grafts, that is, grafts bearing transplantation antigens 
different from those of the donor or host. These experiments demonstrated further the 
increased antigenicity of skin in relation to other tissues. The author hypothesizes that 
additional non-MHC skin antigens may be responsible for the rejection. Additional aspects 
of skin antigenicity are described above (Murray, 1971, Nasir et al., 2009, Tobin et al., 2009, 
Akdis, 2010, van den Berg et al., 2011, Kaplan, 2010, del Rio et al., 2010).  
Adding ALG to a protocol that includes azathioprine and prednisolone may reduce the toxic 
effects of ALG. Corticosteroids such as prednisolone reduce the inflammatory response, 
interfere with protein synthesis and are cytotoxic for lymphocytes. Despite the lymphocyte 
toxicity, these reagents were not found to prolong skin graft survival. The cytotoxic and 
antimetabolite drugs appeared to target DNA function, activity, or synthesis. 
Cyclophosphamide is a strong DNA cross-linker and alkylating agent. Methotrexate is a 
folic acid inhibitor that blocks DNA synthesis, and therefore interferes with cell division in 
lymphocytes. Azathioprine and 6-mercaptopurine are two related purine analogs that have 
been show to delay graft rejection. The effect of all of these drugs was variable depending 
on the species treated and the regimen used. Optimum regimen included using the drugs in 
combination with the specific antigen in order to have a more prolonged graft-protecting 
effect rather than a temporary dampening of the body’s ability to mount an immune 
response.  
2.2 Protection of rabbit skin by phenothiazine derivatives 
Eyal and associates (1965) used phenothiazine related products to suppress immune 
responses to rabbit skin allografts. The team focused their attention on the action of three 
different compounds: chlorpromazine, perphenazine, or promethazine. They chose these 
reagents because of reports that these compounds could minimize cell death and tissue 
necrosis, albeit a protective effect was not witnessed with the engraftment of guinea pig 
skin. Eyal and colleagues hypothesized that an optimal dose and specific compound 
combination would be protective. These compounds produced different degrees of graft 
protection in controlled experiments where they were tested against normal saline in 
otherwise untreated animals. Both treatment and control groups of rabbits were given ear 
skin allografts of approximately equal sizes. They found that the most beneficial compound 
was promethazine, followed by perphenazine; and that the least protective was 
chlorpromazine. They attribute the extended skin graft survival of treated animals to a 
membrane protective effect of the drugs on graft recipient cells and to a reduced loss of 
donor antigen from the graft itself.  
2.3 Prolongation of graft survival mediated by methylhydrazine derivatives   
Floersheim (1967) used methylhydrazine derivatives to induce tolerance in MHC disparate 
adult mice and reported significant improvement in graft prolongation when the treatment 
was combined with an infusion of donor specific cells derived from spleen or from kidneys 
and liver. Graft survival was increased to at least twenty percent when this combined 
therapeutic approach was used. According to the US Environmental Protection Agency 
(EPA) these drugs may have a negative impact on liver and kidney primarily, and on blood 
and spleen secondarily (EPA, 2007). Acute but not chronic effects have been reported for 
humans (EPA, 2007). Thus despite some benefits in terms of graft survival, potentially 
harmful side effects limited more widespread use. 
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2.4 The use of urethane in combination with X-irradiation to protect skin grafts 
Cole and Davis  (1962) used a reagent known as a DNA antagonist and an inhibitor of 
mitosis in order to prolong survival of skin grafts in sub-lethally X-irradiated mice. They 
were aware of studies that demonstrating that high doses of radiation could protect a 
graft by suppressing an immune response. Cole and Davis hypothesized that a lower 
radiation dose in combination with urethane treatment would be immunoprotective and 
showed that sixty percent of the mice had significant skin graft survival. Mean graft 
survival in the treated animals was 40 days vs. 18 days for untreated mice of the same 
strain. Their study included an early attempt to develop irradiation bone marrow 
chimeric mice. A subsequent study induced skin graft tolerance that endured for more 
than 130 days and was specific for transplantation antigens of the bone marrow donor, as 
third party grafts were rejected (Davis and Cole, 1963). In such experiments, the native 
bone marrow is ablated, in whole or in part, by radiation, and specific donor derive bone 
marrow is used to replace the ablated cells of the host. Additional examples of irradiation 
bone marrow chimerism appear below.  
More recently, urethane or polyurethane has been used as a dressing to promote wound 
healing of split thickness skin graft donors (Cigna et al., 2009), and as a component of 
negative pressure dressings for young burn  patients who receive skin grafts (Psoinos et al., 
2009).  
2.5 Calcineurin inhibitors  
Calcineurin is a protein phosphatase found in eukaryotic cells whose activity is  significantly 
blocked by cyclosporine A and Fk506, now referred to as tacrolimus (Rusnak and Mertz, 
2000). The once-popular calcineurin inhibitors (CNI) fell out of favor due to their observed 
nephrotoxicity (Groetzner et al., 2004). Additional complications of the use of CNI drugs 
include associated malignancies. Doesch et al. (2010) studied the development of neoplasias 
in cardiac patients treated with immunosuppressive drugs. They found a strong correlation 
between the use of CNIs or the drug azathioprine and the development of malignancies. 
These drug-associated malignancies include multiple forms of skin cancer, including 
squamous cell carcinoma (Wu et al., 2010), but exclusive of melanoma (Signorell et al., 2010). 
In contrast, the rate of malignancies was reduced in patients treated with non-CNI based 
agents such as mammalian target of rapamycin (m-TOR) inhibitors (Doesch et al., 2010).  
3. Pre-engraftment reduction of tissue antigenicity 
3.1 Cultured tissues and antibodies 
Jacobs and Uphoff (1974) reviewed a variety of methodologies used to reduce the potential 
immune reaction between the donated tissue or organ and the graft recipient and reported 
that phenotypic changes including reduced antigenicity may be observed in cultured cells. 
These changes vary with species. The advantage of using these techniques may be a reduced 
dependence on the use of immunosuppressive agents. Antibodies may be used to treat the 
graft donor or the tissue itself. They summarized the experiments of Hellman and Duke 
(1967) who used a skin allograft model to demonstrate the reversal of tolerance to syngeneic 
skin when the tissue was incubated with skin of a MHC disparate donor. Unpredictably, 
pre-incubating donor and recipient skin together did not result in prolonged skin allograft 
survival.  
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3.2 Preconditioning with allogeneic RNA or DNA 
In agreement with this data, the benefits of altering donor skin antigenicity was further 
demonstrated when Guttman et al. (1964) prevented acceptance of syngeneic skin grafts by 
pretreating mouse skin  in vitro with allogeneic RNA. In contrast to these results, Lemperle 
et al. (1968) demonstrated that pre-treating donor tissue with RNA or DNA facilitated 
extended skin graft survival in MHC disparate donor and host combinations. 
4. The use of chimerism to protect engrafted tissues 
4.1 Bone marrow chimerism induced by whole body Irradiation 
An early model of irradiation induced bone marrow chimerism was developed by two 
scientist working at the National Institute of Allergy and Infectious Disease (Liacopoulos 
and Goode, 1964). Liacopoulos and Goode were aware that overwhelming the immune 
system of potential tissue donors with a bolus of strong antigens from different sources may 
block reactivity to a specific unrelated antigen. This procedure is known as protein 
overloading and is directed towards the graft donor. The group tested the hypothesis that 
spleen cells, bone marrow or skin from animal models given a large dose of antigen would 
be tolerated in another animal. The graft recipients were irradiated and pretreated with 
donor strain derived cells prior to skin grafting. Rabbit gamma globulin or Limulus 
hemocyanin served as the strong antigens. The authors used both a mouse allograft model 
and a concordant rat-to-mouse xenograft model (Liacopoulos and Goode, 1964). 
Owen et al. (1945)  had observed earlier that naturally occurring tolerance could develop 
between dizygotic calves in utero. Since these calves each had a different immunological 
makeup, the prenatal exposure to each other’s disparate antigenic makeup was 
undoubtedly the source of the immunological unresponsiveness. Stone et al. (1965) 
expanded the initial findings by engrafting skin between dizygotic twins known to be 
chimeric at the erythrocyte level. The discovery of chimerism in these calves provided the 
scientific basis for adapting this concept to the development of irradiation bone marrow 
chimerism as a model for the induction of transplantation tolerance.  
Following these discoveries, a series of studies tested the hypothesis that the phenomenon 
of chimerism could be experimentally induced in order to prolong allograft survival (Matheʹ 
et al., 1963, Seller, 1967, Lubaroff and Silvers, 1973, Buckley, 1975). Mathe‘ et al. (1965) 
applied this concept in order to protect a patient from leukemia. The patient was given 
whole body irradiation followed by a bone marrow transplant comprised of tissues from six 
different male and female donors, all of whom were related to the host. The bone marrow 
graft restored the myeloid and erythroid compartments. A skin graft from one of the male 
bone marrow donors remained intact and viable for more than seven months, while skin 
grafts from other donors were rejected. These results implied that the donor and the host 
were more histocompatible. More recent applications of irradiation bone marrow chimerism 
are discussed below.  
Tolerance to allografts following whole body irradiation has been reviewed (Strober et al., 
1979, Slavin et al., 1985, Sprent et al., 1993, Monaco, 2004). A potential mechanism to explain 
the success of these grafts was suggested by Okada and Strober (1982)who used a mixed 
lymphocyte reaction (MLR) to demonstrate that spleen cells from animals given whole body 
irradiation induced the proliferation of large numbers of cells directed against specific  
antigenic targets. This work extended earlier studies that identified two distinct populations 
of suppressor cells induced by these methods. One population responded specifically to 
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bovine serum albumin (BSA) as an antigen, while the other responded non-specifically 
(Slavin and Strober, 1979).  
4.2 The induction of chimerism without myeloablation 
Several investigators have reported the induction of allogeneic bone marrow chimerism 
without myeloablation (Sykes, 1996, Pan et al., 2003, Fuchimoto et al., 2000, Shapira et al., 
2003, Matthews et al., 2004, Ciurea and Andersson, 2009, Przepiorka et al., 1999). 
Myeloablation refers to the massive radiation induced destruction of the host’s bone 
marrow cells, especially the T cell lineages, and the use of allogeneic bone marrow to replace 
the destroyed cells. Because of the radiation, with or without other treatments, the host is 
unable to reject the donated bone marrow cells. The major side effects associated with lethal 
whole body irradiation, have caused some investigators to develop non-myeloablative 
procedures (Sykes, 1996).  
4.2.1 Chimerism to induce tolerance to allografts and xenografts 
Sykes used low dose (3 Gy) whole body irradiation in combination with a higher dose (7 
Gy) irradiation of the thymus and antibodies that deplete CD4+ and CD8+ T cells to generate 
specific tolerance to the cells and tissues of the donor (Sykes, 1996). Sykes used this protocol 
to show tolerance to allografts in the mouse, and tolerance of rat skin in murine hosts. She 
used the swine–to–mouse model to show that the protocol could be expanded to a 
discordant model, that is, one involving hyperacute reactions between widely disparate host 
and donor species. She depleted T cells and natural killer cells (NK) in thymectomized mice, 
then engrafted the thymus of a fetal pig. These mice were shown to accept a skin graft from 
the same donor strain as the thymus graft. Despite being described as “non-myeloablative, 
the procedure combines low dose total body irradiation with focused high level irradiation 
targeted to the thymus. 
4.2.2 Irradiation-free chimerism in a murine allograft model  
Pan et al. (2003) used a combination of costimulation blockade and a metabolism antagonist 
to reduce the donor T cell population in donor bone marrow to induce chimerism in mice. 
Depletion of donor T cells reduced the risk of graft vs. host disease (GVDH) wherein donor 
T cells initiate an immune response against the new host. Pan and colleagues used a 
combination of fludarabine, described below, the immunosuppressive drug 
cyclophosphamide, and interruption of the CD40/CD154 T cell activation pathway to 
facilitate donor bone marrow engraftment. The protocol resulted in mixed chimerism in the 
host and allowed donor origin skin grafts to survive. 
4.2.3 Irradiation-free chimerism in a swine animal model  
Fuchimoto and colleagues (2000) developed a technique to create a hematopoietic system 
composed of both donor origin and host origin cells, referred to as “mixed chimerism” to 
distinguish the results from full chimerism that often occurs when the host is given lethal 
irradiation followed by an allogeneic bone marrow transplant. They used high doses of stem 
cells separated from peripheral blood to induce mixed chimerism. The chimeric host 
accepted skin grafts from a donor whose transplantation antigens (swine leukocyte antigens, 
SLA) matched those of the bone marrow, but did not accept skin grafts from a third party 
donor, one that matched neither the bone marrow donor nor the new host. 
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4.2.4 Irradiation-free chimerism in humans 
Shapira et al. (2003) reported an attempt to induce chimerism with no radiation in high risk 
patients who were not able to tolerate whole body radiation. The use of the drugs 
fludarabine and busulfan had a myeloablative effect on the host bone marrow cells. 
Fludarabine has been reported to minimize the development of neoplasias as well as to 
suppress metabolism (Matthews et al., 2004). Busulfan has been described as a 
myeloablation agonist that has been used to engraft bone marrow and stem cells (Ciurea 
and Andersson, 2009, Przepiorka et al., 1999). Eight percent of the patients developed full 
chimerism as evidence by donor origin hematopoietic cells. Regrettably, graft-versus-host 
disease (GVHD) was identified in most patients despite a brief low dose treatment of 
cyclosporine-A, and mortality was high.   
5. Costimulation blockade to interrupt the process of T cell activation 
If the events reported by Stone’s group represent naturally occurring prenatal tolerance 
(Stone et al., 1965), how then may we induce tolerance in an adult?  One answer may be 
found by dissecting the pathway for the development of immunity. These experiments 
tested the hypothesis that interference with one of the key steps leading to an 
immunological response would prevent the downstream events from occurring. This type of 
tolerance is referred to as peripheral tolerance as it leaves the host with the ability to 
respond to other immunological perturbans. Exposure of untreated animal models to a 
source of foreign antigen initiates the process of immunity and may provide the stimulus to 
recruit potentially alloreactive or xenoreactive cells from their histological sites. Subsequent 
interference with the reaction between CD40 and CD40L (CD154) or the reaction between B7 
molecules and   cytotoxic T lymphocyte-associated antigen (CTLA)-4 provides a scenario 
wherein cells that recognize the foreign antigen receive the initiating signal that recruits 
them to the site of antigen deposit, but not the required secondary signals. Costimulation 
blockade may be mediated by monoclonal antibodies directed against specific cell surface 
molecules, by the use of agonistic monoclonal antibodies to prevent reactivity induced by 
donor origin cells within the graft, referred to as graft-versus-host disease, (Albert et al., 
2005, Yu et al., 2003, Yu et al., 2000) by the use of anti-sense RNA to facilitate apoptosis (Yu 
et al., 2004), or by deletion of cellular components expressing costimulation molecules. In 
systems where CD4 cells are important, graft survival may be accompanied by the 
expansion of CD4+ CD25 Foxp3 regulatory cells. 
When the elements of one’s own immune system come into contact with particles, agents, 
cells or tissues not belonging to the host, those foreign agents are recognized as non-self. 
Immunity is the complex process of activating the body’s adaptive immune defenses in 
order to protect the body from these specific invading elements. T cells are components of 
the adaptive immune system, and as such may be geared up to protect the body from 
foreign invaders, including pathogenic organism and transplanted cell and tissue grafts. 
They are increasingly protective upon re-exposure of the organism to the same antigen 
(Janeway C.A. et al., 2001).  
An important feature of immunity is the activation of thymus derived lymphocytes or T 
cells. Grakoui et al. (1999) provided a detailed study of the environment and the molecular 
interactions required for T lymphocyte activation. In a host with an intact immune system, 
immunity would result in the destruction of engrafted tissue or organs from another 
individual who is not an identical twin. T cell activation is an essential feature of immunity, 
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and thus a significant player in the acceptance or rejection of a graft. A hypothesis utilizing 
this information might be stated as follows: If T cell activation is important for immunity 
and graft rejection, then interruption of the T cell activation cascade will prevent or delay 
graft rejection. Preventing an immune reaction between graft and host would provide an 
environment conducive to transplantation tolerance. In particular, preventing an immune 
response to the specific graft-associated antigens, often described as anergy, would be more 
beneficial than a generalized immunosuppressive response because the host immune 
system would still be capable of protecting the body from other invaders. 
Modern transplantation immunology owes a great debt to the pioneering work of Jenkins 
and Schwartz (1987) who demonstrated that antigen presentation devoid of a MHC context 
failed to stimulate T cell clones in vitro or T cells in vivo. They used a chemical crosslinking 
agent to affix pigeon cytochrome peptides to the surface of spleen cells. If properly 
presented with the cell’s MHC surface molecules, the process would have resulted in T cell 
proliferation, IL-2 production (Jenkins et al., 1987) and antigen recognition (Jenkins and 
Schwartz, 1987). The inappropriate antigen presentation resulted in T cells unresponsive to 
their cognate (recognizable) antigen; and thus the authors concluded that the mechanism 
involved was the deletion of antigen-specific T cells (Jenkins and Schwartz, 2009). Their in 
vitro blockade of T cell activation was reproduced in the mouse model.  
In 1993, Boussiotis et al. (1993) published their research implicating the costimulatory 
molecule B7 as a contributor to allograft immunity. Using a transfection model, the authors 
showed that interrupting the B7:CD28/CTLA4 pathway was consistent with an anergy 
model of immune unresponsiveness to one specific human derived transplantation antigen, 
HLA-DR7. In contrast, blocking the reaction between the intercellular adhesion molecule 1 
(ICAM1) and lymphocyte function antigen 1 (LFA1) appeared to be associated with 
immunosuppression. Important contributors to T cell activation have been reviewed by 
Wingren et al. (1995) and include the work of Ford and Larsen (2009). The work of Jenkins, 
Schwartz, and colleagues has shown antigen specific T cell unresponsiveness (Jenkins et al., 
1987, Jenkins and Schwartz, 1987, Jenkins and Schwartz, 2009). Further research led to 
clarification of the mechanisms of T cell signaling and activation. One set of stimulatory 
reactions was a consequence of the binding of B7 (CD80 or CD86) with CD28; while a 
different cascade of events followed the binding of CD40 with CD154 (CD40L). Many 
features of these pathways were elaborated by Bluestone et al. (1995) and have been 
reviewed by Lenschow et al. (1996). The three main pathways of T cell activation have been 
described by ML Ford and CP Larsen (2009). 
Larsen et al. (1996) showed the importance of interrupting CD40/CD28 binding in skin and 
cardiac allografts, although mechanistic details remained for future investigations. Some 
mechanisms may include the induction of anergy, as mentioned above, the reduction of 
alloreactive T cell populations (Iwakoshi et al., 2000), the induction of regulatory T cells and 
the interactions of other cells with regulatory functions (Gordon and Kelkar, 2009), as 
discussed below, or diverting the proliferation of a specific T cell type (Li et al., 2009). Pree 
et al. have been advocates of the translational aspect of costimulation blockade. In a clinical 
setting, these protocols may facilitate mixed chimerism and prevent a GVH reaction that 
may otherwise ensue (Pree et al., 2009, Pan et al., 2003). 
5.1 The B7/CD28 pathway and skin grafts 
Preventing binding of B7 molecules on B cells to their ligands, CD28 on T cells has been 
shown to be effective for interrupting T cell activation. Shiao et al. (2007) used a humanized 
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antibody directed against the T cell CD28 molecule to prevent the expansion of alloreactive 
T cells. The experiments were done in beige/SCID mice bearing human skin grafts and 
infused with peripheral blood cells expressing different human transplantation antigens 
(HLA) than those of the skin donor. Liu et al. (2007)  used a gene therapy model to infuse 
antisense B7.1 in order to suppress alloreactivity to rat spleen cells. This model was not 
associated with GVHD as measured by examination of intestines, liver, skin, or other 
tissues(Liu et al., 2007). Rulifson et al. (2002) demonstrated that Langerhans cells resident in 
the skin of the donor were such effective antigen presenting cells (APCs) that they could 
prime T cells for activation independently of either the B7 or CD40 activation pathways. In 
their hands, the strength of this direct antigen presentation reaction limited the success of 
tolerance induction mediated through the interruption of either B7-CD28 or CD40-CD154 
pathway. These findings are consistent with the work of Tao et al. (1997) who concluded 
that weak T cell receptor (TCR) signaling primed CD4+cells in a CD28/B7 dependent 
manner. Early experiments using the skin allograft model were important for demonstrating 
that additional costimulatory molecules must be important for completing the T cell 
activation cascade (Kawai et al., 1996). Their report demonstrated suppressed proliferation 
and cytokine production by CD28 depleted T cells, nonetheless, these cells were capable of 
initiating skin allograft rejection.  
5.2 Interrupting CD40 and B7 ligation 
The combined effect of blocking the CD28 and CTLA4 ligation reactions was tested in a 
murine skin graft model (Li et al., 2006). The combined treatment was delivered via a 
replication incompetent adenovirus vector. Significant skin graft survival was 
demonstrated in the treated mice in contrast to rapid rejection of skin grafts in mice that 
were untreated or given non-expressing vectors. A detailed study outlining the efficacy of 
CTLA4Ig produced by different sources as an efficient tool for interrupting costimulatory 
signals produced by the ligation of B7/CD28 molecules was completed (Najafian and 
Sayegh, 2000). CTLA4Ig’s higher affinity for B7 competitively inhibits B7/CD28 ligation, 
therefore interfering with the delivery of costimulatory signals. Other investigators found 
that CTLA4 signaling facilitated allograft survival of skin and islet grafts in mice treated 
with an infusion of donor derived antigen plus ant-CD154 monoclonal antibody (mAb) 
(Zheng et al., 1999). Tung et al. (2008) showed the combined effect of blockading both the 
B7 and CD40 pathways in a series of limb graft experiments. Balb/c male mice were 
donors of limbs engrafted onto C57Bl/6 female mice heterotopically. Costimulation 
blockade was mediated by anti-CD154 antibody with or without CTLA4-Ig. Anti-CD154 
alone resulted in limb survival of 75 days, but graft survival was extended to 120 days by 
the combined therapy. Larsen et al. (1996) demonstrated the advantage of blocking both 
of these costimulatory pathways in order to facilitate the engraftment of skin and cardiac 
tissue. Both in vivo and in vitro confirmation of the effect was discussed. 
Protracted survival of murine  skin allografts in thymectomized mice treated with an 
infusion of donor derived spleen cells and anti-CD154 mAb was achieved only in mice 
expressing CD4+  T cells, gamma interferon, and CTLA4 (Markees et al., 1998). In contrast, 
the studies by Gordon et al. (1998) using the concordant rat-to-mouse xenotransplantation 
model, showed no requirement of CD4+  T cells or for gamma interferon  for prolonging the 
survival of rat skin and islets in mice. The role of B7/CD28 ligation in providing 
costimulatory signals to effect T cell activation was confirmed by the studies of Onodera et 
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al. (1997). They pre-sensitized Lewis rats with Brown-Norway skin grafts and evaluated the 
survival of cardiac grafts when recipients were treated with CTLA4Ig with or without an 
infusion of donor antigen. They hypothesized that graft survival was mediated by either 
clonal anergy or the deletion of alloreactive CD8+ cells. 
5.3 Interfering with CD40/CD154 ligation 
Although the first study of the CD40/CD154 pathway to promote graft survival utilized a 
concordant rat-to-mouse islet xenograft model (Markees et al., 1996), the first use of this 
system to facilitate skin graft acceptance was reported by Larsen at al. (1996), and   
described aspects of the costimulatory process related to both CD28-B7 ligation and CD40-
gp39 ligations. The “gp39” designation was later changed to CD154 in keeping with the 
system for naming cell surface molecules. In their hands, each set of costimulatory 
molecules provides necessary but not identical signals resulting in fully activated T 
lymphocytes. Interrupting both of these pathways provided conditions for prolonged 
survival of heart tissue and skin allografts. 
Interrupting the reaction between CD40 and CD154 has been confirmed as an effective 
method for limiting T cell costimulation. This pathway is required for the generation of T 
cells that are fully activated against alloantigen  (Yamada and Sayegh, 2002), and 
interruption of this pathway promotes graft survival or tolerance. Moodycliffe et al. showed 
that the binding of these molecules encouraged the migration of dendritic cells from the skin 
to the lymph nodes for effective antigen presentation (Moodycliffe et al., 2000). Their model 
assessed dendritic cell (DC) function in wild type C57Bl/6 mice or those devoid of CD154 
molecules. A combined therapy consisting of a bolus infusion of donor derived spleen cells 
and a brief course of treatment with anti-CD154 mAb resulted in prolonged survival of rat 
skin grafts in mice. Graft survival was enhanced significantly in mice devoid of  CD4+  T 
cells (Gordon et al., 2001).  
Nikolic et al. used a skin graft model to differentiate between models that blocked immunity 
to alloantigens vs. those that interrupted autoimmunity (Nikolic et al., 2010). They used 
normoglycemic non obese diabetic mice (NOD) that received whole body irradiation, T cell 
depletion, and anti-CD154 mAbs with or without bone marrow cells from C57Bl/6 mice. 
The treatment delayed or prevented hypoglycemia, but only prevented isletitis in mice that 
received bone marrow cells as well as the other conditioning treatments. 
Xu et al. (2010) studied the role of minor histocompatibility antigens in bone marrow grafts. 
They found that when they used B10.BR skin to sensitize AKR mice to alloantigens, donor 
origin cells were cleared more rapidly than in unsensitized mice of the same strain. 
Recipient mice treated with antibodies to CD154 did not produce antibodies to minor 
histocompatibility antigens of the donor. These studies suggest that blockade of CD40-
CD154 ligation may facilitate bone marrow transplantation and reduce the risk of reactivity 
to minor histocompatibility antigens. 
Although blockade of CD40 and CD28 activation pathways did not produce the 
vasculopathy shown with other methods, translating this method into a clinical protocol 
was unexpectedly problematic because of the development of thromboembolisms 
(Yamada and Sayegh, 2002). Scientists have since analyzed the cause for the 
pathophysiological problems identified clinically. Their reports help to identify platelets 
as a source for soluble CD154 or CD40 ligand and demonstrate a correlation between 
increased circulating levels of this molecule and increased thrombus formation (Yacoub et 
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al., 2010, Yuan et al., 2010). These studies show further that CD154’s concentration is 
increased in hypertensive patients included non-diabetic and pre-diabetic persons with 
metabolic syndrome (Unek et al., 2010).  
In an effort to overcome these complications, Gilson et al. (2009) compared two different 
isotypes   of anti-CD40 monoclonal antibodies. Isotypes are any one of the five main 
structurally and functionally distinct categories of antibodies (Janeway C.A. et al., 2001). 
Gilson et al. (2009) found that the IgG2b, but not the IgG1 antibody had a synergistic effect 
on graft survival when combined with CTLA-4-Ig, and hypothesized that the use of 
alternative antibody isotypes may encourage the development of new reagents that are as 
effective as anti-CD154 antibodies, but without harmful clinical effects.  
6. The induction of regulatory T cells (Tregs) 
In 1975, Gelfand and Paul (1975) used an anti-thy1.2 antibody to facilitate C57Bl/6 skin 
grafts on Balb/c mice. The antibody, which was directed against thymocytes, resulted in 
prolonged skin graft survival in comparison to untreated mice. The study demonstrated 
infectious tolerance as the effect could be transferred to new hosts given cells of the treated 
mice. The authors thus hypothesized that the treatment generated a population of 
suppressor cells that regulated the processes responsible for graft survival. In the same year, 
Gershon hypothesized the existence of suppressor T cells that down modulated immune 
responses and detailed predominant requirements for their functionality (Gershon, 1975). 
These concepts were controversial at the time that they were advanced.  
During the 1980’s, the concept began to take hold that there existed a specific population of 
regulatory T lymphocytes with the capacity to specifically suppress immune responses. 
Maki et al. showed that B6AF1 mice pretreated with ALS and given both BMC and skin 
grafts from CH3 donor mice had suppressed reactivity against donor antigen as 
demonstrated by in vitro assays (Maki et al., 1981a, Maki et al., 1981b). Streilein and 
Niederkorn (1985) described the induction of a suppressor T cell population that helps to 
explain the phenomenon of the anterior chamber of the eye functioning as an 
immunologically privileged site. The suppressor activity was associated with improved skin 
graft survival and other host responses. The suppressor cells were described as Thy1.2 and 
L3T4 expressing CD4+ T lymphocytes.  
Subsequent studies by Subba and Grogan (1986) using rat skin allografts implanted in the 
anterior eye chamber resulted in minimal alloreactivity as measured in vitro. Treatment 
with cyclophosphamide or removal of the allograft reversed the immunosuppression seen 
in mixed lymphocyte reactions (MLR), thus implicating the involvement of suppressor 
cells.  
Based on a wealth of more recently generated data, the scientific community no longer 
needs to be convinced that a regulatory cell population exists or can be induced. Regulatory 
T cells have been identified or induced by some of the methods shown in Table 1 below. We 
now accept the description of the predominant category of regulatory cells responsible for 
allograft survival, the generation of chimerism and mixed chimerism, protection from 
autoimmunity and reduced risk of graft vs. host disease (GVHD) and  host vs. graft disease 
(HVG) as being CD4 + CD25 +Foxp3 + regulatory T lymphocytes. These Tregs may be 
naturally occurring in the thymus or adaptively induced in response to foreign antigen and 
costimulation blockade (Guo et al., 2008, Schwartz, 2005, Sakaguchi, 2005, Coenen et al., 
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2005, von Boehmer, 2005). The Tregs express the forkhead transcription factor Foxp3 
(Fontenot and Rudensky, 2005), and there is some evidence that the expression level of this 
transcription factor may be a key indicator of the level of immunosuppression potential 
(Chauhan et al., 2009) The immunosuppressive effect of these cells has been shown by in 
vivo and in vitro experiments. 
 
 
Graft or Target Authors Method of Induction 
Skin grafts 
Autoimmunity 
(Oderup et al., 2006) 
Il2Rbeta-/- recipients 
 
Heart (Oderup et al., 2006) 
Rag 1 -/- given anti-154 and anti-B7 
 
Chimerism (Iudaev et al., 1975) Sublethal WBI and BMC 
Hy antigen and HVG (Weng et al., 2007) Sublethal WBI 
Chimerism 
Skin allografts 
(Yamazaki et al., 2007) BMC, DST and anti-CD154 
Skin graft (Chai et al., 2005) 
Foxp3 transduced expression in naïve 
CD4+ CD25_ 
Skin graft (Banuelos et al., 2004) 
DST and anti-CD154 in CD4, CD8, or 
CD25 depleted skin and islet graft 
recipients 
Skin graft 
(Sanchez-Fueyo et al., 
2007) 
Wt or Class II – mice 
 
Skin graft 
Mixed chimerism 
(Pilat et al., 2010) 
Rapamyacin and costimulation 
blockade; 
Skin graft (Kim et al., 2011) Anti-CD154, Non cytolytic anti-CD4 
Composite tissue 
allograft 
(Bozulic et al., 2011) Anti-TCR, WBI 
 
Legend: Table 1 describes some milestones in the history of regulatory T cell recognition. Abbreviations: 
WBI, whole body irradiation, BMC, bone marrow cells; HVG, host vs. graft reaction; Hy, male specific 
antigen; DST, donor specific antigen; wt, wild type; TCR, T cell Receptor 
Table 1. The Induction of CD4 + CD25 + Regulatory T Cells 
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7. Other cells with regulatory functions 
7.1 Double negative T cells 
Double negative T cells, described as CD3+ T lymphocytes bearing typical ┙┚T cell receptors, 
but expressing no CD4, CD8, or NK1.1 surface molecules. These cells use the process of 
trogocytosis to gain access to the alloantigen, xenoantigen, or self peptides that are then 
expressed on their cells surfaces (Ford McIntyre et al., 2008). Trogocytosis is the process of 
utilizing broken pieces of plasma membrane as an antigen capture mechanism (Hudrisier et 
al., 2007). B and T cell receptors as well as some costimulatory co-receptors appear to be 
involved in this process. 
7.2 CD8
+
 T cells 
CD8+ T cells have been shown to promote skin allograft survival in fully mismatch donor-
host combinations. Graft survival was initiated by rapamycin treatment of graft hosts (El 
Essawy et al., 2011). El Essawy and colleagues found that C57Bl/6 mice devoid of CD4 
molecules handily rejected DBA mouse skin allografts, but showed prolonged (median 
survival, >100 days) survival of these grafts following rapamycin treatment of the grafts 
hosts. These regulatory/suppressor T cells were CD28 + but showed low levels of IFN-┛, IL-
2, and IL-10.  
7.3 Natural Killer T (NKT) cells 
Natural Killer T (NKT) cells are lymphocytes bearing TCR T cell receptors. A regulatory 
role for these cells was described in mice devoid of the J┙18 segment of the TCR and in 
mice lacking the CD1 restricting element associated with NKT cells following 
costimulation blockade mediated by a transfusion of donor antigen and a short course of 
anti-CD154 mAb (Gordon and Kelkar, 2009). Graft survival was abbreviated in the J┙18 
and in the CD1 deficient mice as compared to wild type mice of the same strain (Gordon 
and Kelkar, 2009). 
7.4 Induction of tolerogenic dendritic cells 
Adorini and Penna (2009) report on the use of vitamin D receptor (VDR) agonist as a means 
of inducing tolerogenic dendritic cells (DCs). These DC are associated with an 
immunosuppressive effect. The use of secosteroid hormones that function as VDR agonist 
help to induce DCs that then facilitate the induction of CD4(+) CD25(+) Foxp3(+) regulatory 
T cells. 
8. The humanized mouse as a model for the study of the human immune 
system 
The humanized mouse model takes advantage of the existence of basic cellular 
deficiencies in non-obese diabetic (NOD) and CB-17 scid/scid strains of mice. Some strains 
are crosses between the two and bear the deficiencies of each parental type. The severe 
combined immunodeficient substrain lacking a functional IL-2 receptor gamma gene has 
become a more advanced mouse model. These mice may be infused with human 
hematopoietic stem cells that reconstitute a functional human immune system in the 
murine environment. These genetically altered mice provide important tools for studying 
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autoimmunity, cellular and molecular interactions of the human immune system, solid 
tumors and other forms of cancer, and may provide models for studying human 
retroviruses or other infections where no appropriate animal model exists. Many of these 
strains have been developed by Lenny Schultz and others at Jackson Laboratories (Bar 
Harbor, ME). Some phenotypic characteristics of the most recent strain include the lack of 
T cells, B cells, and NK cells. There is no IL-2R ┛ chain, both the innate and adaptive 
compartments of the immune system are defective, and most antibody responses are very 
low. Salient features of these mice including timelines for their development have been 
reviewed recently (Van Duyne et al., 2009, Ishikawa et al., 2008, Hill et al., 1991). In the 
section below, we review the use of this important model for investigation in several areas 
of biomedical research.  
8.1 Humanized mouse system for the study of skin grafts and wound healing 
Racki et al. (2010) compared usage of NOD-scid IL2rgamma(null) mouse (NSG) vs. the 
CB17-scid bg (SCID.bg) mouse to study skin allograft survival vs. rejection. They found 
that components of the human immune successfully engrafted into the NSG mouse, but 
that skin graft survival was poor. In contrast, the SCID.bg mouse was less successful in 
engrafting human cells, but showed improved skin graft survival over the NSG model. 
Their results showed that infiltration of transplanted human skin by glucocorticoid 
receptor isoform 1 (GR-1+) cells impaired graft survival. GR-1+ cells are immature myeloid 
cells that may differentiate into dendritic cells, have been identified in human bone 
marrow recipient, and are characterized as having an immunosuppressive effect (Li et al., 
2004). When Racki’s team treated NSG mice with antibodies to GR1, the cellular infiltrate 
decreased and skin graft survival was improved. Additional studies that impact skin graft 
survival and wound healing used an alternative model, the nude mouse (Escamez et al., 
2004). This mouse lacks a thymus, and therefore has no mature T lymphocytes. They 
found that treating laboratory engineered “skin equivalent” with keratinocyte growth 
factor improved wound healing. 
Gilet et al. (2009) used SCID mice reconstituted with human PBLs and engrafted with 
human skin to study T cell subset recruitment mediated by the cytokine CCL17. Erdage and 
Morgan (2004) used the same animal model (huPBMC-SCID) to study the differences in allo- 
and xenoreacivity to bioengineered skin modified with or without keratinocyte growth 
factor. The team used the same model to study the survival of human fetal vs. neonatal skin 
grafts. They found that the lower MHC Class I and Class II expression in fetal skin was 
associated with longer graft survival than that of neonatal skin (Erdag and Morgan, 2002). 
Issa et al. (2010) separated regulatory T cells from human PBLs and used them to control 
immune responses to skin allografts in a humanized mouse model.  
8.2 The humanized mouse system and autoimmunity 
The humanized mouse model has become an important research tool for the study of type 1 
diabetes and psoriasis. Pearson et al. (Pearson et al., 2008) described the NOD-Rag1null 
Prf1null Ins2Akita spontaneously hyperglycemic mouse model. This model has no 
autoimmune defect, but may be used to study type 1 diabetes in an environment that avoids 
any toxicity associated with chemically induced diabetes models. King et al. (2008) describe 
the engraftment of peripheral blood mononuclear cells (PBMC) vs. human stem cells. They 
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induced diabetes and showed that an infusion of allo-PBMCs leads to islet graft rejection, 
thus they proposed the use of this model to study mechanisms of human islet allograft 
rejection. Other aspects involving the use of these animal models to study diabetes have 
been reviewed (King et al., 2008, Shultz et al., 2007). 
Humanized mouse models of psoriasis have been developed that use bioengineered skin 
derived from biopsies and from patients with psoriasis (Guerrero-Aspizua et al., 2010). A 
psoriasis pathology was duplicated by injecting cultivated T cell populations along with IL-
17and IL-22, and depriving the skin of its stratum corneum. This model will be used to 
assess the pathophysiology of the disease and to suggest alternative therapeutic targets, and 
to test new hypothesis related to patient outcomes in pre-clinical investigations. 
Bhagavathula et al. (2005) used the severe combined immunodeficient (SCID) mouse to 
demonstrate the effectiveness of humanized neutralizing mAbs directed against transduced 
amphiregulin as a therapeutic agent reversing some phenotypic characteristics of psoriasis 
in transplanted skin. The mAb decreased epidermal thickness in vivo and reduced 
keratinocyte growth in vitro. 
Because TNF┙ antagonists have been used to counter the effects of psoriasis, Gordon et al. 
(2005) used a humanized mAb directed against TNF┙ to dissect the mechanism of action of 
these reagents. They injected the reagent into otherwise unaffected skin engrafted onto the 
SCID-HU mouse model and they injected highly activated T cells in order to simulate an 
acute psoriasis phenotype. The concentration of epidermal Langerhans cells (LCs) in the 
plaques began to increase within one week of the mAb treatment, and thus the loss of LCs 
was associated with plaque development. These studies help to clarify the method of action 
of the TNF┙ antagonist and suggest a method for reversing the course of this disease in 
patients.  
8.3 The humanized mouse system and immunity: Graft vs. Host Disease (GVHD) 
This model has been used to study GVHD. Soluble FasL was used to treat graft recipients 
in order to prevent alloreactivity of immunocompetent donor T cells that recognize the 
host antigens (Bohana-Kashtan et al., 2009). Pinot et al. (2010)  describe the development 
of the NSG mouse model and its use in studying xeno-GVHD. Vlad et al. (2009) used this 
mode to demonstrate the prevention of GVHD through the use of an immunoglobulin 
component, the immunoglobulin-like transcript 3-Fc protein, that induces CD8+ 
suppressor cells. 
8.4 The humanized mouse system as a source for induced pluripotent stem cells 
Hanna et al. (2007) used a humanized mouse model of sickle cell anemia to describe the 
benefits of using induced pluripotent stem cells (IPS) derive from adult fibroblast cells. This 
“knock-in” model replaced mouse globin genes with mutated human A┛ and ┚S globin 
genes. The homozygous mutant developed many phenotypic characteristics of the sickle cell 
disease. Tail snips from these mice were used as a source of fibroblast cultures. Retroviral 
vectors were used to transduce expression of the four transcription factors needed to 
reprogram the adult mouse cells or to express selectable markers. The investigators used 
homologous recombination to repair the genetic defect responsible for sickle cell disease. 
The investigators anticipate future studies that eliminate the use of retroviral vectors and 
oncogenes in applications of IPS for human use.  
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9. Conclusions 
The modern world of skin grafting, arising from its historical roots to new depths of 
scientific understanding, will help to advance translational science and medicine. Skin grafts 
allow us to understand specific immunological functions, help dissect the mechanisms 
responsible for tissue and organ specific tolerance, identify additional regulatory cells or 
functions required for transplantation tolerance, test the development of mouse models of 
the human immune system and help answer fundamental questions related to the use of 
stem cells as curative agents for human disease. 
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The procedure of skin grafting has been performed since 3000BC and with the aid of modern technology has
evolved through the years. While the development of new techniques and devices has significantly improved
the functional as well as the aesthetic results from skin grafting, the fundamentals of skin grafting have
remained the same, a healthy vascular granulating wound bed free of infection. Adherence to the recipient bed
is the most important factor in skin graft survival and research continues introducing new techniques that
promote this process. Biological and synthetic skin substitutes have also provided better treatment options as
well as HLA tissue typing and the use of growth factors. Even today, skin grafts remain the most common and
least invasive procedure for the closure of soft tissue defects but the quest for perfection continues.
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